Delving into the Latest Updates on Malaria vaccine(Pevion Biotech AG) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

Malaria vaccine

+ [8]

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

MalariaMalaria, Falciparum

Originator Organization

Pevion Biotech AG

Active Organization-

Inactive Organization

Swiss Tropical & Public Health Institute

Mymetics Corp.Pevion Biotech AG

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Author: Deye, Gregory A ; Strauss, Kathleen A ; Butts, Jessica ; Cox, Catherine ; Travassos, Mark A ; Joshi, Sudhaunshu ; Regules, Jason A ; Pasetti, Marcela F ; Bergmann-Leitner, Elke S ; Friedman-Klabanoff, DeAnna J ; Mo, Annie X ; Lundeen, Jordan S ; Berry, Andrea A ; Laurens, Matthew B ; Shrestha, Biraj ; Nomicos, Effie Y H ; Shriver, Mallory

AbstractBackgroundMalaria is preventable yet causes >600 000 deaths annually. RTS,S, the first marketed malaria vaccine, has modest efficacy, but improvements are needed for eradication.MethodsWe conducted an open-label, dose escalation phase 1 study of a full-length recombinant circumsporozoite protein vaccine (rCSP) administered with adjuvant glucopyranosyl lipid A–liposome Quillaja saponaria 21 formulation (GLA-LSQ) on days 1, 29, and 85 or 1 and 490 to healthy, malaria-naive adults. The primary end points were safety and reactogenicity. The secondary end points were antibody responses and Plasmodium falciparum parasitemia after homologous controlled human malaria infection.ResultsParticipants were enrolled into 4 groups receiving rCSP/GLA-LSQ: 10 µg × 3 (n = 20), 30 µg × 3 (n = 10), 60 µg × 3 (n = 10), or 60 µg × 2 (n = 9); 10 participants received 30 µg rCSP alone × 3, and there were 6 infectivity controls. Participants experienced no serious adverse events. Rates of solicited and unsolicited adverse events were similar among groups. All 26 participants who underwent controlled human malaria infection 28 days after final vaccinations developed malaria. Increasing vaccine doses induced higher immunoglobulin G titers but did not achieve previously established RTS,S benchmarks.ConclusionsrCSP/GLA-LSQ had favorable safety results. However, tested regimens did not induce protective immunity. Further investigation could assess whether adjuvant or schedule adjustments improve efficacy.Clinical Trials RegistrationNCT03589794

01 Jun 2024·iScience

Targeting PfProhibitin 2-Hu-Hsp70A1A complex as a unique approach towards malaria vaccine development

Article

Author: Goswami, Bidhan ; Munjal, Akshay ; Ramalingam, Sivaprakash ; Marothia, Manisha ; Anand, Sakshi ; Biswas, Shreeja ; Shevtsov, Maxim ; Abdulhameed Almuqdadi, Haider Thaer ; Behl, Ankita ; Shoaib, Rumaisha ; Gupta, Pragya ; Biswas, Saurav ; Kahlon, Amandeep Kaur ; Singh, Shailja ; Kumari, Geeta ; Saini, Monika ; Bhowmick, Ipsita Pal ; Garg, Swati ; Maurya, Preeti ; Ranganathan, Anand

Malaria parasite invasion to host erythrocytes is mediated by multiple interactions between merozoite ligands and erythrocyte receptors that contribute toward the development of disease pathology. Here, we report a novel antigen Plasmodium prohibitin "PfPHB2" and identify its cognate partner "Hsp70A1A" in host erythrocyte that plays a crucial role in mediating host-parasite interaction during merozoite invasion. Using small interfering RNA (siRNA)- and glucosamine-6-phosphate riboswitch (glmS) ribozyme-mediated approach, we show that loss of Hsp70A1A in red blood cells (RBCs) or PfPHB2 in infected red blood cells (iRBCs), respectively, inhibit PfPHB2-Hsp70A1A interaction leading to invasion inhibition. Antibodies targeting PfPHB2 and monoclonal antibody therapeutics against Hsp70A1A efficiently block parasite invasion. Recombinant PfPHB2 binds to RBCs which is inhibited by anti-PfPHB2 antibody and monoclonal antibody against Hsp70A1A. The validation of PfPHB2 to serve as antigen is further supported by detection of anti-PfPHB2 antibody in patient sera. Overall, this study proposes PfPHB2 as vaccine candidate and highlights the use of monoclonal antibody therapeutics for future malaria treatment.

100 Deals associated with Malaria vaccine(Pevion Biotech AG)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05144

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Malaria, Falciparum	Phase 2	GB	Pevion Biotech AG	01 Aug 2005
Malaria	Phase 2	-	Swiss Tropical & Public Health Institute	-
Malaria	Phase 2	-	Pevion Biotech AG	-
Malaria	Phase 2	-	Mymetics Corp.	-